Veterinary medicinal products containing paromomycin to be administered parenterally to pigs

Current status:
European Commission final decision

Overview

On 18 July 2019, the European Medicines Agency recommended suspending the marketing authorisations for paromomycin antibiotics given to pigs by injection into a muscle. The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of these medicines do not outweigh their risks because of inadequate data supporting their use in pigs and the possibility of bacterial resistance.

Key facts

Approved name
Veterinary medicinal products containing paromomycin to be administered parenterally to pigs
International non-proprietary name (INN) or common name

Paromomycin

Associated names
  • Parofor
  • Gabbrovet
  • Gabbrocol
Reference number
EMEA/V/A/129
Type
Article 35

Community interest referral: initiated in cases involving the interests of the Community or concerns relating to the protection of human or animal health or the environment.

Status
European Commission final decision
Opinion date
18/07/2019
EC decision date
11/10/2019

All documents

Document description

  • Opinion - contains the CVMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents may not always be available:

How useful was this page?

Add your rating